WHAT IS
HORMONE THERAPY?
Hormone therapy β also called endocrine therapy β treats cancers that depend on oestrogen or testosterone to survive and grow. By reducing hormone levels or blocking their receptors, it can halt or reverse tumour progression with a more targeted side-effect profile than conventional chemotherapy.
analyticsAt a Glance
- check_circleHormone-sensitive breast cancer (ER+/PR+) accounts for 70β75% of all breast cancers β the largest hormone therapy population in oncology
- check_circleProstate cancer is hormone-sensitive in nearly all cases β androgen deprivation therapy is the foundation of systemic treatment
- check_circleHormone therapy works through three main mechanisms: reducing hormone production, blocking hormone receptors, or stopping the pituitary from signalling the gonads
- check_circleHormone therapy is usually taken for 5β10 years in breast cancer β duration and tolerability are as important as drug selection
What Is Hormone Therapy and How Is It Different from Chemotherapy?
Chemotherapy kills rapidly dividing cells throughout the body β it is effective but non-selective, causing the well-known side effects of nausea, hair loss, and immunosuppression. Hormone therapy is a targeted intervention that specifically interrupts the hormonal signalling that hormone-sensitive cancer cells depend on to survive. Rather than killing all rapidly dividing cells, it removes a specific growth signal β often leaving hair, immune function, and the gastrointestinal tract largely unaffected.
βHormone therapy does not kill cancer cells directly β it removes the growth signal they depend on and creates an environment in which they cannot thrive. This is why it can work for years without the acute toxicity of chemotherapy.β
How Hormones Drive Cancer Growth
Oestrogen and progesterone bind to receptors inside cancer cells β triggering DNA transcription that promotes cell division. In ER-positive breast cancer, every oestrogen molecule that enters a cell acts like a key that unlocks a growth programme. Testosterone has the same role in prostate cancer via the androgen receptor. Removing the hormone removes the key β and the growth programme stalls.
The Three Mechanisms of Hormone Therapy
All hormone therapies work through one of three mechanisms: (1) reducing hormone production β aromatase inhibitors, GnRH agonists, orchiectomy; (2) blocking hormone receptors β tamoxifen, fulvestrant, enzalutamide; or (3) blocking the pituitary signal that drives gonadal hormone production β GnRH agonists like goserelin and leuprolide. Many treatment plans combine mechanisms β ovarian suppression plus aromatase inhibitor, for example.
Which Cancers Are Treated with Hormone Therapy?
Hormone therapy is most commonly used in breast and prostate cancer, but it plays important roles across several other tumour types.
| Cancer Type | Hormone Dependency | Primary Hormone Therapy Agents | Role |
|---|---|---|---|
| Breast cancer (ER+/PR+) | Oestrogen and progesterone receptors drive growth | Tamoxifen, aromatase inhibitors, fulvestrant, CDK4/6 inhibitors + AI | Adjuvant (5β10 years); metastatic first-line |
| Prostate cancer | Androgen receptor drives growth in virtually all cases | GnRH agonists/antagonists, bicalutamide, enzalutamide, abiraterone, ARDT | All stages from localised to metastatic castration-resistant |
| Uterine / endometrial cancer | Progesterone receptors in well-differentiated tumours | Megestrol acetate, medroxyprogesterone, levonorgestrel IUD | Recurrent low-grade; fertility-sparing in young patients |
| Ovarian cancer (low-grade serous) | Oestrogen receptor positive in ~70% of LGSOC | Letrozole, tamoxifen, megestrol β primarily for LGSOC | Maintenance after surgery or salvage at recurrence |
| Thyroid cancer (DTC) | TSH drives growth of differentiated thyroid cancer (DTC) | Levothyroxine suppression to TSH <0.1 mU/L | Adjuvant TSH suppression post-thyroidectomy for intermediate/high-risk DTC |
| Adrenal cortical carcinoma | Cortisol secretion; some oestrogen dependency | Mitotane (adrenolytic); ketoconazole; osilodrostat for Cushing's control | Adjuvant mitotane; symptom control of hormone excess |
Hormone Therapy Drug Classes: A Reference Guide
A structured overview of the main hormone therapy drug classes used in breast and prostate cancer β the two indications with the most extensive clinical evidence.
| Drug Class | Mechanism | Examples | Primary Use | Menopausal Status Relevant? |
|---|---|---|---|---|
| SERMs (Selective Oestrogen Receptor Modulators) | Blocks oestrogen receptor in breast; partial agonist in bone/uterus | Tamoxifen, toremifene | Breast cancer β pre- and post-menopausal | Yes β tamoxifen used both; AIs only post-menopausal |
| Aromatase Inhibitors (AIs) | Blocks aromatase enzyme β prevents peripheral oestrogen production | Letrozole, anastrozole, exemestane | Breast cancer β post-menopausal (or with OFS) | Yes β only effective when ovarian oestrogen eliminated |
| SERDs (Selective Oestrogen Receptor Degraders) | Binds and degrades oestrogen receptor | Fulvestrant, elacestrant, camizestrant | Metastatic ER+ breast cancer (2nd line +) | No β used in both |
| GnRH Agonists | Downregulates pituitary LH/FSH β suppresses gonadal hormones | Goserelin, leuprolide, triptorelin | Breast cancer OFS; prostate cancer ADT | Yes β primary OFS tool in premenopause |
| GnRH Antagonists | Directly blocks GnRH receptor β no testosterone flare | Degarelix, relugolix | Prostate cancer ADT β faster castrate level | Yes β prostate cancer only |
| Androgen Receptor Antagonists | Competes with testosterone at androgen receptor | Enzalutamide, darolutamide, apalutamide | Prostate cancer β castration-sensitive and resistant | No |
| CYP17A1 Inhibitors | Blocks androgen biosynthesis in adrenal and tumour | Abiraterone + prednisone | Castration-resistant prostate cancer | No |
| CDK4/6 Inhibitors (with AI or fulvestrant) | Blocks cell cycle β synergistic with endocrine therapy | Palbociclib, ribociclib, abemaciclib | Metastatic ER+ HER2- breast cancer | No |
Hormone Therapy: Key Clinical Numbers
Reference figures that illustrate the scale and impact of endocrine therapy in oncology.
- 70β75%Of breast cancers are ER-positiveMaking hormone-sensitive breast cancer the largest single indication for endocrine therapy in oncology β and tamoxifen/AIs among the most prescribed cancer drugs globally.
- 5β10 yrDuration of adjuvant endocrine therapy (breast cancer)Extended to 10 years for high-risk premenopausal patients on the basis of the ATLAS trial (tamoxifen) and MA.17R trial (letrozole after 5 years).
- 50%Reduction in breast cancer recurrence with 5 years of AI vs tamoxifen (selected trials)AIs outperform tamoxifen in post-menopausal ER+ breast cancer in multiple randomised trials β the ATAC, BIG 1-98, and TEAM trials.
- ~100%Of prostate cancers are androgen-sensitive at initial diagnosisMaking androgen deprivation therapy (ADT) relevant across essentially the entire prostate cancer population at some point in the disease course.
Benefits and Key Considerations of Hormone Therapy
Hormone therapy offers important advantages over chemotherapy in hormone-sensitive cancers β but requires careful attention to long-term side effects, drug interactions, and adherence over multi-year treatment courses.
Benefits
- Oral dosing in most cases β no infusion centre visitsTamoxifen, AIs, enzalutamide, and abiraterone are oral daily tablets β allowing home-based treatment without hospital visits for most of the treatment duration.
- Long-term efficacy sustained over yearsUnlike chemotherapy, which is given in cycles for weeks or months, hormone therapy maintains efficacy over years β the risk reduction from 10 years of tamoxifen continues to accumulate beyond treatment completion.
- Better quality-of-life profile than chemotherapyNo hair loss, minimal nausea, no immunosuppression β hormone therapy allows most patients to maintain near-normal daily activity and work throughout treatment.
- Bone protection possible alongside therapyBisphosphonates (zoledronic acid) and denosumab protect against AI-related or ADT-related bone loss β preventing osteoporosis with concurrent treatment.
Key Considerations
- Menopausal symptoms β hot flushes, night sweatsThe most common hormone therapy side effect across all agents β caused by oestrogen deprivation in breast cancer or testosterone suppression in prostate cancer. Managed with lifestyle measures, venlafaxine, or clonidine.
- Bone loss requires monitoring and preventionAIs in breast cancer and ADT in prostate cancer both cause bone density loss β annual DEXA scan and calcium/vitamin D supplementation are standard alongside hormone therapy.
- Multi-year adherence challengeUp to 30β40% of breast cancer patients discontinue adjuvant endocrine therapy early due to side effects β one of the most important quality and outcome gaps in breast cancer care.
- Drug interactions require reviewTamoxifen is metabolised by CYP2D6 β SSRIs, antipsychotics, and other CYP2D6 inhibitors reduce its efficacy. Full medication review at initiation is essential.
More from the Hormone Therapy Resource Library
Continue exploring endocrine therapy β from receptor status and individual drugs to monitoring and combination strategies.
- ER, PR, and HER2 Status Explained: What the Results Mean
- Tamoxifen: Side Effects, CYP2D6 Interactions, and Monitoring
- Aromatase Inhibitors: Letrozole, Anastrozole, and Exemestane
- Ovarian Suppression for Breast Cancer: Goserelin and Oophorectomy
- Hormone Therapy for Breast Cancer β Complete Guide
- Hormone Therapy for Prostate Cancer β Complete Guide
Frequently Asked Questions
Common questions from patients starting hormone therapy for the first time.
Understanding Hormone Therapy
Is hormone therapy the same as hormonal contraception or HRT?
No β cancer hormone therapy (endocrine therapy) has the opposite goal from both. Hormonal contraceptives and menopausal HRT add synthetic hormones to the body. Cancer hormone therapy reduces or blocks hormones β specifically to deprive cancer cells of the oestrogen or testosterone they need to grow. The drugs, mechanisms, and side-effect profiles are entirely different. Patients on hormone therapy for breast cancer should not take oestrogen-containing HRT during treatment, as it would directly counteract the therapy's mechanism.
Will hormone therapy put me into menopause?
This depends on which drug you receive and your age. Tamoxifen does not stop ovarian function in premenopausal women β periods typically continue or become irregular. Aromatase inhibitors require oestrogen levels to be post-menopausal to be effective; when combined with ovarian suppression (goserelin/leuprolide) in premenopausal women, they do cause a chemical menopause β hot flushes, vaginal dryness, and reduced libido are common. In most cases, ovarian function resumes after ovarian suppression is discontinued. Surgical oophorectomy causes permanent menopause.
Can I stop hormone therapy if the side effects are severe?
You should not stop hormone therapy without first discussing it with your oncologist β but the side effects of all hormone therapy agents are manageable, and there are alternatives if one agent is not tolerated. For tamoxifen intolerance, switching to an aromatase inhibitor (with ovarian suppression if premenopausal) is a reasonable option. For AI intolerance, switching between the three AIs or between AI and tamoxifen often resolves the problem. For bone loss, bisphosphonates co-prescribed with hormone therapy dramatically reduce the impact. Stopping prematurely significantly reduces the recurrence risk benefit β the solution to side effects is nearly always agent switching or symptom management, not discontinuation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Your Hormone Therapy Plan?
CancerFax connects patients with specialist oncologists in China and India who can review your receptor status, prior treatment, menopausal status, and comorbidities to optimise your endocrine therapy regimen β or provide a second opinion on duration and monitoring.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.